Safety and immunogenicity of mRNA-LNP COVID-19 vaccine CVnCoV in Latin American adults: A phase 2 randomized study.
Sáez-Llorens X, Lanata C, Aranguren E, Celis CR, Cornejo R, DeAntonio R, Ecker L, Garrido D, Gil AI, Gonzales M, Hess-Holtz M, Leroux-Roels G, Junker H, Kays SK, Koch SD, Lazzaro S, Mann P, Quintini G, Srivastava B, Vahrenhorst D, von Eisenhart-Rothe P, Wolz OO, Oostvogels L.
Sáez-Llorens X, et al.
Vaccine X. 2022 Aug;11:100189. doi: 10.1016/j.jvacx.2022.100189. Epub 2022 Jul 1.
Vaccine X. 2022.
PMID: 35791320
Free PMC article.